Literature DB >> 15544627

Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.

N Franchimont1, C Reenaers, C Lambert, J Belaiche, V Bours, M Malaise, P Delvenne, E Louis.   

Abstract

Crohn's disease (CD) is associated with low bone mass due to chronic inflammation and other factors. Receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin (OPG) are potentially involved in this process as they regulate osteoclastogenesis and are influenced by pro-inflammatory cytokines. The aim of this study was to determine the levels of soluble RANKL (sRANKL), RANK and OPG expression both in the serum and in the colon of CD patients. Levels of sRANKL and OPG were assessed in the serum and the supernatants of cultured colonic biopsies in patients with CD and controls by ELISA. RANK expression was explored by immunostaining and immunofluorescence of fixed colonic samples. OPG and sRANKL levels were higher in the serum of CD patients as compared to age- and sex-matched controls. Levels of sRANKL and OPG were significantly enhanced in cultured colonic biopsies from CD, and OPG levels correlated with histological inflammation, and pro- and anti-inflammatory cytokine levels. No significant correlation was found for sRANKL. RANK+ cells were increased in the colon of CD, particularly in inflamed areas. These cells were positive for CD68 or S100 protein. We conclude that serum and local levels of sRANKL and OPG are increased in CD. Moreover, RANK is expressed in the colonic mucosa by subpopulations of activated macrophages or dendritic cells at higher levels in CD compared to normal colon.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544627      PMCID: PMC1809233          DOI: 10.1111/j.1365-2249.2004.02643.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.

Authors:  K Ina; J Itoh; K Fukushima; K Kusugami; T Yamaguchi; K Kyokane; A Imada; D G Binion; A Musso; G A West; G M Dobrea; T S McCormick; E G Lapetina; A D Levine; C A Ottaway; C Fiocchi
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

2.  Activation of nuclear factor kappa B inflammatory bowel disease.

Authors:  S Schreiber; S Nikolaus; J Hampe
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 3.  Inflammatory bowel disease: etiology and pathogenesis.

Authors:  C Fiocchi
Journal:  Gastroenterology       Date:  1998-07       Impact factor: 22.682

4.  Fracture risk is increased in Crohn's disease, but not in ulcerative colitis.

Authors:  P Vestergaard; K Krogh; L Rejnmark; S Laurberg; L Mosekilde
Journal:  Gut       Date:  2000-02       Impact factor: 23.059

5.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Authors:  Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

6.  Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production.

Authors:  Z Liu; S Colpaert; G R D'Haens; A Kasran; M de Boer; P Rutgeerts; K Geboes; J L Ceuppens
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

7.  TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells.

Authors:  R Josien; B R Wong; H L Li; R M Steinman; Y Choi
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

8.  Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis.

Authors:  M Boirivant; M Marini; G Di Felice; A M Pronio; C Montesani; R Tersigni; W Strober
Journal:  Gastroenterology       Date:  1999-03       Impact factor: 22.682

9.  TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation.

Authors:  E A Green; R A Flavell
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

10.  TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo.

Authors:  R Josien; H L Li; E Ingulli; S Sarma; B R Wong; M Vologodskaia; R M Steinman; Y Choi
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  18 in total

Review 1.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

2.  Serum correlates of the placebo effect in irritable bowel syndrome.

Authors:  E Kokkotou; L A Conboy; D C Ziogas; M T Quilty; J M Kelley; R B Davis; A J Lembo; T J Kaptchuk
Journal:  Neurogastroenterol Motil       Date:  2009-12-22       Impact factor: 3.598

3.  Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota.

Authors:  Kazuki Nagashima; Shinichiro Sawa; Takeshi Nitta; Masanori Tsutsumi; Tadashi Okamura; Josef M Penninger; Tomoki Nakashima; Hiroshi Takayanagi
Journal:  Nat Immunol       Date:  2017-04-24       Impact factor: 25.606

4.  Induced Sézary syndrome PBMCs poorly express immune response genes up-regulated in stimulated memory T cells.

Authors:  Benjamin F Chong; Patrick Dantzer; Thomas Germeroth; Mikehl Hafner; Adam J Wilson; Guanghua Xiao; Henry K Wong
Journal:  J Dermatol Sci       Date:  2010-07-22       Impact factor: 4.563

Review 5.  Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?

Authors:  Franco Scaldaferri; Carmen Correale; Antonio Gasbarrini; Silvio Danese
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

6.  Microarray analysis reveals the inhibition of nuclear factor-kappa B signaling by aristolochic acid in normal human kidney (HK-2) cells.

Authors:  Ya-yin Chen; Su-yin Chiang; Hsiu-ching Wu; Shung-te Kao; Chien-yun Hsiang; Tin-yun Ho; Jaung-geng Lin
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

7.  Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-κB activation.

Authors:  Lily Nahidi; Steven T Leach; Daniel A Lemberg; Andrew S Day
Journal:  Dig Dis Sci       Date:  2013-09-19       Impact factor: 3.199

Review 8.  Chronic pediatric inflammatory diseases: effects on bone.

Authors:  Anuradha Viswanathan; Francisco A Sylvester
Journal:  Rev Endocr Metab Disord       Date:  2007-12-29       Impact factor: 6.514

9.  A single-nucleotide polymorphism in the gene encoding osteoprotegerin, an anti-inflammatory protein produced in response to infection with diarrheagenic Escherichia coli, is associated with an increased risk of nonsecretory bacterial diarrhea in North American travelers to Mexico.

Authors:  Jamal A Mohamed; Herbert L DuPont; Zhi-Dong Jiang; Jose Flores; Lily G Carlin; Jaime Belkind-Gerson; Francisco G Martinez-Sandoval; Dongchuan Guo; A Clinton White; Pablo C Okhuysen
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

10.  Effects of a GSK-3β inhibitor on the renal expression levels of RANK, RANKL and NF-κB in a rat model of diabetic nephropathy.

Authors:  Yi-Xia Zhou; Li-Xin Shi; Hua Yang; Yi-Guo Long; L U Meng; Li-Sa Lv; Yang Zhang; Huan Yao; Long Li; Yan-Ni Yu
Journal:  Exp Ther Med       Date:  2016-03-24       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.